Rchr
J-GLOBAL ID:200901098080636006
Update date: Jul. 21, 2022
Fukushima Akira
フクシマ アキラ | Fukushima Akira
Contact this researcher
You can send email directly to the researcher.
Affiliation and department:
Taiho Pharmaceutical Co., Ltd. Clinical Data Management and Biostatistics.
About Taiho Pharmaceutical Co., Ltd. Clinical Data Management and Biostatistics.
Search "Taiho Pharmaceutical Co., Ltd. Clinical Data Management and Biostatistics."
Job title:
Project Manager
Research field (1):
Statistical science
Research keywords (10):
抗癌剤
, 市販後調査
, 臨床試験
, データマネジメント
, 生物統計
, Anti-cancer Drug.
, Post Marketing Surveillance
, Clinical Trial
, Data Management
, Biostatistics
Research theme for competitive and other funds (2):
2000 - 生存時間解析に関する研究
2000 - Study for Survival Analysis
MISC (7):
吉村功. 医薬品情報データを理解するための統計モデルの活用. 医薬品情報学. 2009. 10. 4. 256-262
吉村功. 統計科学と健康科学の相互寄与. 小西貞則,国友直人編. 21世紀の統計科学II,自然・生物・健康の統計科学.東大出版会. 2008. 181-213
吉村功. 統計科学と医・薬・生物・健康科学との相互寄与を未来に向けて思量する. 日本統計学会誌. 2007. 37. 1. 37-54
FUKUSHIMA A. Estimating a hazard function for each of four items of adverse event induced by the anti-cancer drug TS-1-Application of slip-mixed log-logistic model for interval censored data-. Japanese Journal of Pharmacoepidemiology. 2006. 11. 1. 9-21
S Mizuno, T Yamaguchi, A Fukushima, Y Matsuyama, Y Ohashi. Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations. CLINICAL TRIALS. 2005. 2. 2. 174-181
more...
Lectures and oral presentations (1):
Estimation of hazard functions for adverse events of anti-cancer drug TS-1 -Application of slip-mixed log-logistic model for interval censored data-.
(The 21th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2005)
Professional career (2):
Master (Science) (Hiroshima University)
Docter(Engineering) (Tokyo University of Science)
Association Membership(s) (2):
薬剤疫学会
, Japanese Society of Pharmacoepidemiology
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM